Colon Cancer Molecular and Targeted Experimental Therapy
Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death in the USA. CRC incidence rates have rapidly increased in several regions where the incidence was historically low, including parts of East Asia and Eastern Europe. In 2014, it was estimated that 136,830 new cases and 50,310 deaths have occurred in the USA and over 1.2 million new cases and some 600,000 deaths have occurred worldwide. The prognosis of CRC declines rapidly with the advanced staging. According to the American Joint Committee on Cancer (AJCC) staging system, the overall 5-year survival of patients with stage I CRC was greater than 90 %, whereas that of the stage IV was less than 10 %. Unfortunately, surgical resection is not suitable for the vast majority of CRC patients who have metastatic disease. As a result, more effective treatment approaches for CRC are needed.
Molecularly Targeted Therapies
Advances in the understanding of cellular and...
KeywordsVascular Endothelial Growth Factor Hepatocyte Growth Factor mCRC Patient Adoptive Cell Therapy Extrinsic Apoptosis Pathway
This work was partially supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney, a National Health and Medical Research Council of Australia (NHMRC) Project grant to LQ (ID: APP1047417), and two Cancer Council NSW grants to LQ (ID: APP1070076) and LH (ID: APP1069733).
- Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16(4):1256–1263CrossRefPubMedGoogle Scholar
- Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P (2014) Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. J Immunother 37(1):26–35CrossRefPubMedGoogle Scholar
- Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, Chresta CM, Gu Y, Zhang J, Wu YL, Wilkinson RW, Guichard SM, Smith PD (2012) Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res 72(7):1804–1813CrossRefPubMedGoogle Scholar
- Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL (2013) Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19(2):462–468PubMedCentralCrossRefPubMedGoogle Scholar
- Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18(8):2316–2325CrossRefPubMedGoogle Scholar
- Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ (2012) Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 18(21):6023–6031CrossRefPubMedGoogle Scholar